As the premier source of global pharmaceutical market intelligence, we create essential value for our clients and deliver strong financial results for our shareowners. IMS (NYSE: RX) is committed to building shareowner value -- a commitment based on our reputation for leadership and innovation, our global coverage, our customer base, our unmatched data assets and our expertise. IMS's financial model is characterized by strong operating leverage, high free cash flow and a predictable revenue stream that provides our business with financial flexibility, balance sheet strength and a high return on investment for our shareholders.  |
IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies|
Powerful Analytical Tool Assesses Cancer Drug Use and Impact of
New Indications in World’s Seven Leading Markets
NORWALK, Conn.--(BUSINESS WIRE)--Nov. 11, 2009--
IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced the upcoming launch of IMS Oncology QuantifierTM,
a comprehensive, clinically rich analytical tool that enables the
company’s clients to ... |
| IMS Health to be Acquired by TPG and CPP Investment Board|
IMS Shareholders to Receive $22 per Share in Cash; Transaction
Valued at $5.2 Billion
NORWALK, Conn.--(BUSINESS WIRE)--Nov. 5, 2009--
IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced that it has entered into a definitive agreement to be acquired
by investment funds managed by TPG Capital (“TPG”) and the CPP
Investment Board (“CPPIB”) in a transac... |
| IMS Health Announces 2009 Third-Quarter Results|
Revenues of $541 million, up 3% over second quarter
GAAP EPS of $(0.05) reflects previously announced restructuring
charge
Non-GAAP EPS of $0.40
Strong preliminary cash flow from operations
NORWALK, Conn.--(BUSINESS WIRE)--Oct. 22, 2009--
IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, ... |
| IMS Health Exploring Strategic Alternatives| NORWALK, Conn.--(BUSINESS WIRE)--Oct. 20, 2009--
IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced that it is exploring a variety of strategic alternatives. The
Company further stated that as part of the process the Board of
Directors has formed a committee, which has retained Foros Securities
LLC as its financial advisor. The Company has retained Deutsche Bank
... |
|
|
| | There are currently no events scheduled. |
|
|
|
